SCHEMBL21687541

SCHEMBL21687541

N#Cc1cc([Si](c2ccccc2)(c2ccccc2)c2ccccc2)cc(C#N)c1-c1cccc(-n2c3ccccc3c3ccccc32)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 5/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
HPGD P15428 3/20 0.39
MAPK1 P28482 2/20 0.39
LMNA P02545 1/20 0.39
KMT2A Q03164 2/20 0.36
TSHR P16473 2/20 0.35
TDP1 Q9NUW8 3/20 0.33
NPSR1 Q6W5P4 2/20 0.33
HIF1A Q16665 1/20 0.33
GABRA1 P14867 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32
MAOA P21397 3/20 0.32
MAOB P27338 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21687519 0.93 KDM4E (0.35) KDM4EATML3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL21687774 0.89 ALDH1A1 (0.39) KDM4EATML3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL21688120 0.88 KDM4E (0.42) KDM4EATML3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL21688241 0.86 KDM4E (0.37) KDM4EATML3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL21687973 0.86 KDM4E (0.39) KDM4EATML3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL21687727 0.86 ALDH1A1 (0.40) KDM4EATML3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL21687817 0.86 KDM4E (0.39) KDM4EATML3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL21688181 0.85 KDM4E (0.36) KDM4EATML3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL24927268 0.84 KDM4E (0.44) KDM4EATML3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL21687925 0.84 KDM4E (0.40) KDM4EATML3MBTL1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11201300-B2 Condensed cyclic compound and organic light-emitting device including condensed cyclic compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2021-12-14 US disclosed
US-20200044168-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND SAMSUNG ELECTRONICS CO., LTD. (KR) 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200044168-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND CRY1, CCNL2, CCNE2 KDM4E 2977/4885ATM 1151/4885L3MBTL1 1003/4885
US-11201300-B2 Condensed cyclic compound and organic light-emitting device including condensed cyclic compound CRY1, CCNL2, CCNE2 KDM4E 2977/4885ATM 1151/4885L3MBTL1 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.